Drug Search Results
More Filters [+]

CX-01

Alternative Names: cx-01, cx 01, cx01
Latest Update: 2024-04-15
Latest Update Note: Clinical Trial Update

Product Description

For the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia; The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) hematopoietic stem cells by disrupting the High-mobility group box protein 1 (HMGB1) interaction with toll-like receptor 4 (TLR4) and receptors for advanced glycation end products (RAGE), the CXC chemokine CXCL12/chemokine receptor 4 (CXCR4) axis, and by disrupting other leukocyte and vascular adhesion molecules. In addition, CX-01 may also help promote count recovery after treatment given its affinity for platelet factor-4 (PF4). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02995655)

Mechanisms of Action: CXCL12 Inhibitor,CXCR4 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chimerix
Company Location: DURHAM NC 27713
Company CEO: Michael A. Sherman
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CX-01

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Myeloid Leukemia

Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CNTX-CX-01-2015-AML-1

P2

Completed

Acute Myeloid Leukemia

2019-06-01

CNTX-CX-01-2016-MDS-1

P1

Completed

Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome

2018-09-13

Recent News Events